

AstraZeneca vaccine.

The situation is very dynamic though. Thus, to support efforts to establishing a common approach to the issue as well as providing each agency with an updated overview of the situation across the Member States, the HMA Management Group hereby launch a second survey.

The HMA Management Group would kindly ask you to provide information in relation to:

1. The number of cases of venous sinus thrombosis together with thrombocytopenia in your country
2. The national approach and actions in relation to the use of the AstraZeneca vaccine in your country (including possible age and gender restrictions, intervals between doses)
3. The use of monoclonal antibodies for covid-19 in your country

Please submit your response on Friday 26 March 2021 at 11:00 CET at the latest.

Subsequently, HMA Permanent Secretariat will summarise the information and provide the Network with an overview of the situation in the Member States before the weekend. In addition, we will try to obtain the review of dosing interval mentioned by 5.1.2e at today's meeting and circulate it together with the results of the updated survey.

On behalf of the HMA Management Group

Best regards,

HMA Permanent Secretariat



Heads of Medicines Agencies Permanent Secretariat

www.hma.eu